Patents Represented by Attorney Joseph E. Zahner
-
Patent number: 8201702Abstract: The invention provides a modular and foldable recycling apparatus for home use. The apparatus contains multiple modules attached in series, which can be separated into individual modules. Each module is made of a foldable frame to hold a container, such as a bag, for the containment, separation and transport of recyclable materials. The apparatus can be folded like an accordion to allow for convenient storage.Type: GrantFiled: February 22, 2008Date of Patent: June 19, 2012Assignee: Harleman Products, LLCInventor: David P. Harleman
-
Patent number: 8092803Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has the amino acid sequence shown in SEQ ID NO:4.Type: GrantFiled: July 9, 2010Date of Patent: January 10, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Eric Furfine, Daniel Dix, Kenneth S. Graham, Kelly Frye
-
Patent number: 7892823Abstract: Disclosed are vectors, kits and methods useful in the construction of recombinant cells and DNAs via enhanced efficiency homologous recombination. The vectors are targeting vectors that contain a gene-of-interest spliced between two ends that are homologous to a genome target site. The ends of the vector may be protected from exonuclease attack by deploying a cap, such as a hair pin structure. The vector is linked to a nuclear localization signal sequence, and preferably, a bait peptide that binds to RAD51, to facilitate homologous recombination. The vector may be deployed in myriad genetic transformation applications, such as site-directed mutagenesis, gene therapy, and the like.Type: GrantFiled: February 6, 2007Date of Patent: February 22, 2011Assignee: Geneprotech, Inc.Inventor: Uthayashanker Ezekiel
-
Patent number: 7803619Abstract: Disclosed are embryoid bodies having a uniform size of approximately 415 nm and comprising genetically modified embryonic stem cells, and methods of making same. The genetically uniform embryoid bodies can be multiplexed as one embryoid body per well in a multiwell format, and used as a high to medium throughput screen for test agents that affect the development and homeostasis of animals, including humans. The genetic modification of the embryonic stem cells is a promoter-report-selection construct that enables the selection and detection of cells of a particular lineage in the EB, to determine the effects of a test agent.Type: GrantFiled: July 9, 2006Date of Patent: September 28, 2010Assignee: Geneprotech, Inc.Inventor: Uthayashanker Ezekiel
-
Patent number: 7718791Abstract: A process for reducing the protein content and preserving the capsular polysaccharide content in a complex cellular Streptococcus pneumoniae lysate broth prior to purification is described. Utilizing pH reduction after cellular lysis has resulted in a purified polysaccharide that consistently meets the protein specification, and higher recovery yields of polysaccharide during the purification process.Type: GrantFiled: March 31, 2006Date of Patent: May 18, 2010Assignee: Wyeth LLCInventors: Brian Bahler, Tsu-shun Lee, Jason Arnold Lotvin, Mark Edward Ruppen, Pamela Sue Fink Charbonneau
-
Patent number: 7709001Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 3 polysaccharide covalently linked to a carrier protein, the method including periodic acid oxidation of the polysaccharide in the presence of bivalent cations.Type: GrantFiled: December 22, 2006Date of Patent: May 4, 2010Assignee: Wyeth LLCInventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso, A. Krishna Prasad
-
Patent number: 7659090Abstract: The present invention provides improved methods for the reduction or removal of protein impurities from a complex cellular Streptococcus pneumoniae lysate or centrate comprising serotype 3 polysaccharides involving steps relating to post-lysis heating or pH adjustment. In certain methods, the lysate is heated for a time and at a temperature sufficient to denature proteins present in the lysate and cause their aggregation and precipitation. In one embodiment, the lysate is heated to at least 60° C. for at least 30 minutes to cause protein aggregation and precipitation, more particularly about 60° C. to about 70° C. for about 30 to about 50 minutes, and even more particularly about 65° C. for about 40 minutes. In other methods, the pH of the lysate or centrate is increased to at least 8.0 to improve filterability, more particularly about 8.0 to 8.4, and even more particularly about 8.2.Type: GrantFiled: October 9, 2007Date of Patent: February 9, 2010Assignee: Wyeth LLCInventors: Brian Douglas Bahler, Erik Heller Hughes, Tsu-shun Lee
-
Patent number: 7655402Abstract: Methods and compositions for treating and diagnosing cancer and screening for agents for such treatment and diagnosis are provided. The methods involve screening for agents that modulate the activity or expression of FOXM1, which has been discovered herein to play a role in cell growth and cell cycle regulation. Methods for treating cancer, methods for modulating the activity or expression of FOXM1, methods for diagnosing a subject that has or is at risk of developing cancer, and pharmaceutical compositions are also provided.Type: GrantFiled: February 4, 2005Date of Patent: February 2, 2010Assignee: Wyeth LLCInventors: Diane R. Wonsey, Maximillian T. Follettie
-
Patent number: 7643943Abstract: Methods, systems and equipment useful for monitoring in vivo activities of CCI-779 or other drugs. Numerous drug activity genes can be identified by the present invention. The expression profiles of these genes in peripheral blood mononuclear cells are modulatable by CCI-779 or other drugs. Therefore, these genes can be used as surrogate markers for detecting or monitoring drug activities in vivo.Type: GrantFiled: March 5, 2004Date of Patent: January 5, 2010Assignee: Wyeth LLCInventors: Michael E. Burczynski, Joseph Boni, Andrew J. Dorner, Natalie C. Twine, Jennifer Stover, William L. Trepicchio, Virginia Fitzpatrick, Fred Immermann
-
Patent number: 7611839Abstract: Methods, systems and equipment for diagnosing renal cell carcinoma (RCC) and other solid tumors. This invention identifies numerous disease genes that are differentially expressed in the peripheral blood of patients having RCC or other solid tumors relative to disease-free humans. These disease genes can be used as surrogate markers for detecting the presence or absence of RCC or other solid tumors.Type: GrantFiled: November 21, 2003Date of Patent: November 3, 2009Assignee: WyethInventors: Natalie C. Twine, Michael E. Burczynski, William L. Trepicchio, Andrew J. Dorner, Jennifer A. Stover, Donna K. Slonim
-
Patent number: 7442767Abstract: Novel calcium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.Type: GrantFiled: June 23, 2004Date of Patent: October 28, 2008Assignee: WyethInventor: Rodrigo Franco
-
Patent number: 7407781Abstract: An oocyte recording chamber for electrophysiological measurements. The recording chamber includes a base and a cover attached to the base. The cover and the base define a chamber having a size sufficient to accommodate an oocyte. The recording chamber includes a first electrode and a second electrode that are positioned so that the tips of the electrodes penetrate the membrane of the oocyte when the cover is fastened to the base. The recording chamber also includes a third electrode and a fourth electrode exposed to the chamber and used as ground electrodes.Type: GrantFiled: May 8, 2003Date of Patent: August 5, 2008Assignee: WyethInventor: Jinliang Sui
-
Patent number: 7345096Abstract: The present invention relates to the use of compounds and composition of compounds that modulate norepinephrine levels for the prevention and treatment of vasomotor symptoms, such as hot flush, caused by, inter alia, thermoregulatory dysfunctions.Type: GrantFiled: October 14, 2003Date of Patent: March 18, 2008Assignee: WyethInventors: Darlene Coleman Deecher, Istvan Jozsef Merchenthaler, Liza Leventhal, Kimberly Jean Sipe, Lawrence Thomas O'Connor
-
Patent number: 7256034Abstract: An chimerical polypeptide that arrests proliferating cells in mitosis is provided. In general the polypeptide has an N-terminal transit peptide, such as HIV-1 Tat, and a C-terminal cell-cycle effector, such as a G2/M cyclin or a cytostatic factor. A polynucleotide under the control of a heterologous promoter that encodes a polypeptide that arrests cells in mitosis is also provided. The polynucleotide may, for example, encode a G2/M cyclin. Pharmaceutical compositions comprising the agent that inhibits transit through mitosis is provided. A method of treating patients suffering from a hyperplasia, such as cancer, psoriasis or benign prostate hyperplasia is provided.Type: GrantFiled: January 5, 2004Date of Patent: August 14, 2007Assignee: Nucleus Remodeling, Inc.Inventor: Joseph Edward Zahner
-
Patent number: 7232893Abstract: The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.Type: GrantFiled: July 9, 2004Date of Patent: June 19, 2007Assignee: Saint Louis UniversityInventors: Ranjit Ray, Ratna Ray, Arnab Basu, Yie-Hwa Chang
-
Patent number: 6673894Abstract: An chimerical polypeptide that arrests proliferating cells in mitosis is provided. In general the polypeptide has an N-terminal transit peptide, such as HIV-1 Tat, and a C-terminal cell-cycle effector, such as a G2/M cyclin or a cytostatic factor. A polynucleotide under the control of a heterologous promoter that encodes a polypeptide that arrests cells in mitosis is also provided. The polynucleotide may, for example, encode a G2/M cyclin. Pharmaceutical compositions comprising the agent that inhibits transit through mitosis is provided. A method of treating patients suffering from a hyperplasia, such as cancer, psoriasis or benign prostate hyperplasia is provided.Type: GrantFiled: February 27, 2002Date of Patent: January 6, 2004Assignee: Nucleus Remodeling, IncorporatedInventor: Joseph E. Zahner